Good cardiologists, who understand the concepts of Vascular Biology and prevention of coronary artery disease— have stayed away from angiotension converting enzyme... receptor blocker. Finding out it metabolizes out to a cancer agent— a real one. This is one huge big deal.
It turns out, from the U of FL Vascular Biology Working Group— that the most tissue selective and specific angiotensin converting enzyme inhibitor (not a receptor blocker)... that stays bound to vulnerable arterial tissue and to target organs that are hurt most by hypertension-— IS: quinapril. Quinapril. I’ll take the cough— for all the benefit vs. how valsartan was sold (and now... cancer?).
Quote: “There is contradictory evidence with regard to treating people with heart failure with a combination of an angiotensin receptor blocker like valsartan and an angiotensin-converting enzyme inhibitor, with two major clinical trials (CHARM-additive and ValHeFt) showing a reduction in death, and two others (VALIANT and ONTARGET) showing no benefits, and more adverse effects including heart attacks.
This interested me because my oldest daughter has taken two drugs from this family and had two seizures. She has now been taken off the drugs by her doctor.
This interested me because my oldest daughter has taken two drugs from this family and had two seizures. She has now been taken off the drugs by her doctor.
Is this med a “biologic”? They seem to be mentioned more and more in the side effects section of many Rx med commercials.